Segall Bryant & Hamill’s ANI Pharmaceuticals ANIP Stock Holding History

Segall Bryant & Hamill’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.72M	Sell	32,860 -1,974	-6%	-$158K	0.03%	411
2026 Q1	$2.68M	Sell	34,834 -1,516	-4%	-$118K	0.04%	386
2025 Q4	$2.87M	Sell	36,350 -668	-2%	-$57.8K	0.04%	383
2025 Q3	$3.39M	Sell	37,018 -1,520	-4%	-$124K	0.05%	353
2025 Q2	$2.51M	Sell	38,538 -2,877	-7%	-$187K	0.04%	400
2025 Q1	$2.77M	Sell	41,415 -2,027	-5%	-$121K	0.04%	388
2024 Q4	$2.4M	Sell	43,442 -1,430	-3%	-$82.1K	0.03%	411
2024 Q3	$2.68M	Buy	44,872 +740	+2%	+$45.1K	0.04%	405
2024 Q2	$2.81M	Buy	+44,132	New	+$2.87M	0.05%	351

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Segall Bryant & Hamill's ANIP Position: Q2 2026 in Review

Segall Bryant & Hamill reduced its ANI Pharmaceuticals (ANIP) stake by 5.7% in Q2 2026, selling an estimated $158K and leaving 32,860 shares worth $2.72M. The position accounts for 0.03% of the portfolio, ranked #411.

Segall Bryant & Hamill first reported a position in ANIP in Q2 2024 and has held it in 9 quarters since. The position peaked at $3.39M in Q3 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Segall Bryant & Hamill held 32,860 shares of ANI Pharmaceuticals worth $2.72M as of Q2 2026.
Segall Bryant & Hamill sold 1,974 ANI Pharmaceuticals shares in Q2 2026, an estimated $158K.
ANI Pharmaceuticals made up 0.03% of Segall Bryant & Hamill's portfolio in Q2 2026, its #411 holding.
Segall Bryant & Hamill first reported a position in ANI Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Segall Bryant & Hamill's ANI Pharmaceuticals position peaked at $3.39M in Q3 2025.
307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.